KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

Authors

Melissa L. Johnson
Sai-Hong Ignatius Ou
Minal Barve
Igor I. Rybkin, Henry Ford HealthFollow
Kyriakos P. Papadopoulos
Ticiana A. Leal
Karen Velastegui
James G. Christensen
Thian Kheoh
Richard C. Chao
Jared Weiss

Recommended Citation

Johnson ML, Ou SHI, Barve M, Rybkin II, Papadopoulos KP, Leal TA, Velastegui K, Christensen JG, Kheoh T, Chao RC, and Weiss J. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. European Journal of Cancer 2020; 138:S2.

Document Type

Conference Proceeding

Publication Date

10-2020

Publication Title

European Journal of Cancer

Volume

138

Issue

Suppl 2

First Page

S2